Londinia Opportunities Analyses - 06/09/2023 (GMT) PHARMANUTRA - 1H

- EUR (-)

- 15 min delayed data - Italy Stocks

Type:	Stocks
Ticker:	PHN
ISIN:	IT0005274094

Londinia

I am delighted to see that my first price objective has been achieved. I hope you've taken advantage of it.

Europe Stocks
Timeframe : 1H
- Analysis generated on
Status : TARGET REACHED

Summary of the analysis

Trends

Short term: Strongly bullish

Underlying: Strongly bullish

Technical indicators

83%

17%

My opinion

Bullish above 59.1 EUR

My targets

61.9 EUR (+3.17%)

63.7 EUR (+6.17%)

My analysis

PHARMANUTRA is part of a very strong bullish trend. Traders may consider trading only long positions (at the time of purchase) as long as the price remains well above 59.1 EUR. The next resistance located at 61.9 EUR is the next bullish objective to be reached. A bullish break in this resistance would boost the bullish momentum. The bullish movement could then continue towards the next resistance located at 63.7 EUR. After this resistance, buyers could then target 68.0 EUR. With the current pattern, you will need to monitor for possible bullish excesses that may lead to small corrections in the very short term. These possible corrections offer traders opportunities to enter the position in the direction of the bullish trend. Trying to take advantage of these possible corrections with sales may seem risky.

Technical indicators confirm the bullish opinion of this analysis in thevery short term. However, be careful of excessive bullish movements. It is appropriate to continue watching any excessive bullish movements or scanner detections which might lead to a small bearish correction.

Force

8.8

Analysis too old. There are no more charts available.

Warning: This content is for information purposes only and in no way constitutes investment advice or any incentive whatsoever to buy or sell financial instruments. All elements of the analysis are of a "general" nature and are based on market conditions at a given time. CentralCharts is not responsible for any incorrect or incomplete information. Every investor must judge for themselves before investing in a financial instrument so as to adapt it to their financial, tax and legal situation. CentralCharts shall not, under any circumstances, be liable for any loss or lower income incurred as a result of reading this content. Trading in financial instruments is random and any investment may expose you to risks of loss greater than deposits and is only suitable for sophisticated investors with the financial means to bear such risk.

Additional analysis

Quotes

PHARMANUTRA rating 60.0 EUR. The price has increased by +2.39% since the last closing and was traded between 58.5 EUR and 60.2 EUR over the period. The price is currently at +2.56% from its lowest and -0.33% from its highest.

58.5

60.2

60.0

The Central Gaps scanner detects a bearish opening marking the presence of sellers ahead of buyers at the opening but not sufficiently marked to allow the price to register a quotation gap.

Bearish opening

Type : Bearish

Timeframe : Openning

A study of price movements over other periods shows the following variations:

The study of the highest / lowest by the Central Records scanner shows the following result:

New HIGH record (1 month)

Type : Bullish

Timeframe : Weekly

Technical

Technical analysis of PHARMANUTRA in 1H shows a strongly overall bullish trend. 92.86% of the signals given by moving averages are bullish. The overall trend is supported by the strong bullish signals from short-term moving averages. The Central Indicators market scanner currently does not detect any result that concerns moving averages.

An assessment of technical indicators shows a strong bullish signal.
The Central Indicators scanner found this result concerning these indicators:

Price is back over the pivot point

Type : Bullish

Timeframe : Weekly

The analysis of the price chart with Central Patterns scanners does not return any result.

No result was found by the Central Candlesticks scanner on Japanese candlesticks.

ProTrendLines

Price

	S3	S2	S1	Price	R1	R2	R3
ProTrendLines	57.4	58.5	59.1	60.0	61.9	63.7	68.0
Change (%)	-4.33%	-2.50%	-1.50%	-	+3.17%	+6.17%	+13.33%
Change	-2.6	-1.5	-0.9	-	+1.9	+3.7	+8.0
Level	Intermediate	Major	Major	-	Minor	Intermediate	Intermediate

To determine price objectives, it is also possible to use the pivot points. Here is the price position in relation to pivot points:

Daily

Pivot points	S3	S2	S1	PP	R1	R2	R3
Standard	57.5	58.0	58.3	58.8	59.1	59.6	59.9
Camarilla	58.4	58.5	58.5	58.6	58.7	58.8	58.8
Woodie	57.4	58.0	58.2	58.8	59.0	59.6	59.8
Fibonacci	58.0	58.3	58.5	58.8	59.1	59.3	59.6

Weekly

Pivot points	S3	S2	S1	PP	R1	R2	R3
Standard	55.5	56.4	57.8	58.7	60.1	61.0	62.4
Camarilla	58.5	58.7	58.9	59.1	59.3	59.5	59.7
Woodie	55.7	56.5	58.0	58.8	60.3	61.1	62.6
Fibonacci	56.4	57.3	57.9	58.7	59.6	60.2	61.0

Monthly

Pivot points	S3	S2	S1	PP	R1	R2	R3
Standard	43.5	47.0	52.8	56.3	62.1	65.6	71.4
Camarilla	56.1	57.0	57.9	58.7	59.6	60.4	61.3
Woodie	44.8	47.6	54.1	56.9	63.4	66.2	72.7
Fibonacci	47.0	50.5	52.7	56.3	59.8	62.0	65.6

Numerical data

The following are the details of the technical indicators and moving averages that were collected to generate this technical analysis:

Technical indicators

Moving averages

RSI (14):	71.30
MACD (12,26,9):	0.2000
Directional Movement:	32.4
AROON (14):	78.6
DEMA (21):	59.3
Parabolic SAR (0,02-0,02-0,2):	58.7
Elder Ray (13):	0.6
Super Trend (3,10):	58.7
Zig ZAG (10):	60.0
VORTEX (21):	1.0000
Stochastique (14,3,5):	74.80
TEMA (21):	59.4
Williams %R (14):	-11.80
Chande Momentum Oscillator (20):	1.5
Repulse (5,40,3):	0.7000
ROCnROLL:	1
TRIX (15,9):	0.0000
Courbe Coppock:	1.90

MA7:	59.0
MA20:	58.2
MA50:	55.4
MA100:	57.5
MAexp7:	59.4
MAexp20:	59.0
MAexp50:	58.8
MAexp100:	58.4
Price / MA7:	+1.69%
Price / MA20:	+3.09%
Price / MA50:	+8.30%
Price / MA100:	+4.35%
Price / MAexp7:	+1.01%
Price / MAexp20:	+1.69%
Price / MAexp50:	+2.04%
Price / MAexp100:	+2.74%

Quotes : - 15 min delayed data - Actions Italie

News

Don't forget to follow the news on PHARMANUTRA. At the time of publication of this analysis, the latest news was as follows: